New drug cocktail aims to wipe out HER2 breast cancer before surgery

NCT ID NCT07635342

Recruiting now Disease control Sponsor: Hebei Medical University Fourth Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a combination of targeted drugs (pyrotinib and trastuzumab) plus chemotherapy can completely eliminate HER2-positive breast cancer before surgery. About 182 women with early-stage disease will receive 8 cycles of treatment. The main goal is to see if no cancer remains in the breast or lymph nodes after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pyrotinib, trastuzumab, pegylated liposomal doxorubicin, cyclophosphamide, paclitaxel
What this could lead to: If successful, this combination could become a standard pre-surgery treatment to eliminate HER2-positive breast cancer before surgery, potentially improving long-term outcomes.
What could go wrong: This is a Phase 2 trial with only 182 participants, so results are preliminary. The drug combination may cause side effects like heart problems or severe infections, and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE BREAST CANCER

Contacts and locations

Locations

The Fourth Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, Hebei, 050000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.